Topas Therapeutics GmbH
This profile has not been verified by the business owner.
Information may be incomplete or outdated.
Overview
Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying treatments for autoimmune and inflammatory diseases.
At Topas we are developing a proprietary platform of antigen-specific nanoparticle conjugates, called TPCs (Topas Particle Conjugates) uniquely positioned to address major unmet need in T-cell mediated diseases in a targeted manner.
TPCs are uniquely engineered to restore and promote immune tolerance by targeting liver sinusoidal endothelial cells (LSECs) and harnessing antigen-specific immune tolerance mechanisms of the liver.
Our technology has delivered to date two clinical candidates: TPM203 (Phase 1 pemphigus vulgaris) and TPM 502 (Phase 2 celiac disease).
Contact Details
info@topas-therapeutics.com
Hamburg, Germany
Employees
20-30
Categories
Keywords
You're invisible in searches for:
Add keywords that describe your company, services, or market to improve your visibility in search results.
Companies teams usually look at after Topas Therapeutics GmbH
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.